The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Baseline and longitudinal ctDNA biomarkers in GEICAM/2013-02 (PEARL) trial cohort 2 comparing palbociclib and fulvestrant (PAL + FUL) versus capecitabine (CAPE).
 
Javier Pascual
No Relationships to Disclose
 
Miguel Martin
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Other Relationship - Novartis; Roche
 
Paula Proszek
No Relationships to Disclose
 
Miguel Gil-Gil
Honoraria - Esteve; Novartis; Pierre Fabre; Roche
Consulting or Advisory Role - AstraZeneca Spain; Daiichi Sankyo
 
Alistair Reay
No Relationships to Disclose
 
Christoph Zielinski
Honoraria - AstraZeneca; Athenex; Imugene; MSD; Roche
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Athenex; Bristol-Myers Squibb (Inst); Fibrogen (Inst); Imugene; Lilly (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); SERVIER (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Patent Property, Imugene
 
Jesus Herranz
No Relationships to Disclose
 
Ros Cutts
No Relationships to Disclose
 
Manuel Ruiz-Borrego
Honoraria - AstraZeneca Spain; Daiichi Sankyo; Novartis; Pfizer; Roche
 
Andrew Feber
No Relationships to Disclose
 
Eva M. Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Claire Swift
No Relationships to Disclose
 
Montserrat Muñoz
Consulting or Advisory Role - Pierre Fabre; Seagen
Expert Testimony - Eisai; Novartis; Roche
Travel, Accommodations, Expenses - Lilly; Pfizer; Roche
 
Begona Bermejo
Consulting or Advisory Role - AstraZeneca Spain; MSD; Novartis; Pierre Fabre; Roche; Seagen
Speakers' Bureau - Daiichi Sankyo; Eisai; MSD; Palex; Pfizer; Roche
 
Mireia Margelí
Consulting or Advisory Role - Novartis; Pfizer; Pierre Fabre; Roche
Research Funding - AstraZeneca (Inst); Eisai (Inst); Kern Pharma (Inst); Roche (Inst)
 
Yuan Liu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Isaac Garcia-Murillas
No Relationships to Disclose
 
Michael Hubank
Honoraria - Boehringer Ingelheim; Incyte (Inst); Qiagen
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Guardant Health; Illumina; Janssen; Kuchar; Lilly; Merck Serono; Novartis; Roche
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Repare Therapeutics; Roche; Taiho Pharmaceutical; Zeno pharmaceuticals
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)